Our results, strictly based on analyses of chemotherapy-naïve tumour samples from patients with synchronous metastatic disease, also demonstrate an inter-patient heterogeneity regarding known driver mutations, which is in line with previously published data on CRC, with TP53, APC, and KRAS being the most frequently mutated genes57,61. Here, TP53 is linked to neoplasm.